Prelude Therapeutics Appoints CMO With 30 Years’ Experience for 2026 Trials
Prelude Therapeutics named Dr. Charles Morris as Chief Medical Officer effective April 20, 2026, bolstering its leadership with 30 years of oncology drug development experience. Morris’s track record advancing therapies like Faslodex and elacestrant will guide Prelude’s two lead programs targeting myeloproliferative neoplasms and ER+ breast cancer into clinical development.
1. Appointment Details
Dr. Charles Morris will join Prelude Therapeutics as Executive Vice President and Chief Medical Officer effective April 20, 2026, filling a key strategic role on the leadership team.
2. Executive Background
Morris brings over 30 years of oncology drug development experience from roles at Lava Therapeutics, Celyad Oncology, Radius Health and AstraZeneca, where he led programs including Faslodex and elacestrant.
3. Clinical Pipeline Impact
He will oversee the clinical development of Prelude’s two lead programs targeting myeloproliferative neoplasms and ER+ breast cancer, both slated to enter clinical trials in 2026, and guide regulatory interactions.